Acetylcholine receptor and behavioral deficits in mice lacking apolipoprotein E

Neurobiology of Aging

Volumn 32, Issue 1, 2011, Pages 75-84

  Siegel, Jessica A ^a   Benice, Theodore S ^a   Van Meer, Peter ^a   Park, Byung S ^b   Raber, Jacob ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Acetylcholine; Alzheimer's disease; Apolipoprotein E; Attention; Muscarinic; Stress

Indexed keywords

ACETYLCHOLINE; APOLIPOPROTEIN E; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; BRAIN CORTEX; CONDITIONING; CONTROLLED STUDY; EYELID REFLEX; GENOTYPE; HIPPOCAMPUS; MALE; MOUSE; NEUROTRANSMISSION; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR BINDING; TASK PERFORMANCE; WILD TYPE;

ACOUSTIC STIMULATION; ANALYSIS OF VARIANCE; ANIMALS; APOLIPOPROTEINS E; BEHAVIORAL SYMPTOMS; BRAIN; CHOICE BEHAVIOR; CHOLINERGIC ANTAGONISTS; CORTICOSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; FEMALE; GENE EXPRESSION REGULATION; MALE; MICE; MICE, KNOCKOUT; NEURAL INHIBITION; PROTEIN BINDING; REACTION TIME; RECEPTORS, MUSCARINIC; REFLEX, ACOUSTIC; SCOPOLAMINE;

EID: 78449303426     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2008.12.006     Document Type: Article

References (66)

1. Allen S.J., MacGowan S.H., Tyler S., Wilcock G.K., Robertson A.G., Holden P.H., Smith S.K., Dawbarn D. Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype. Neurosci. Lett. 1997, 239:33-36.
2. Anderson R., Higgins G.A. Absence of central cholinergic deficits in ApoE knockout mice. Psychopharmacology (Berl.) 1997, 132:135-144.
3. Arendt T., Schindler C., Bruckner M.K., Eschrich K., Bigl V., Zedlick D., Marcova L. Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. J. Neurosci. 1997, 17:516-529.
4. Arnold H.M., Burk J.A., Hodgson E.M., Sarter M., Bruno J.P. Differential cortical acetylcholine release in rats performing a sustained attention task versus behavioral control tasks that do not explicitly tax attention. Neuroscience 2002, 114:451-460.
5. Ballmaier M., Casamenti F., Scali C., Mazzoncini R., Zoli M., Pepeu G., Spano P.F. Rivastigmine antagonizes deficits in prepulse inhibition induced by selective immunolesioning of cholinergic neurons in nucleus basalis magnocellularis. Neuroscience 2002, 114:91-98.
6. Bao S., Chen L., Thompson R.F. Classical eyeblink conditioning in two strains of mice: conditioned responses, sensitization, and spontaneous eyeblinks. Behav. Neurosci. 1998, 112:714-718.
7. Berger-Sweeney J. The cholinergic basal forebrain system during development and its influence on cognitive processes: important questions and potential answers. Neurosci. Biobehav. Rev. 2003, 27:401-411.
8. Bhatnagar S., Costall B., Smythe J.W. Hippocampal cholinergic blockade enhances hypothalamic-pituitary-adrenal responses to stress. Brain Res. 1997, 766:244-248.
9. -/- mice. Neuropsychopharmacology 2004, 29:441-449.
10. Bronfman F.C., Tesseur I., Hofker M.H., Havekens L.M., Van Leuven F. No evidence for cholinergic problems in apolipoprotein E knockout and apolipoprotein E4 transgenic mice. Neuroscience 2000, 97:411-418.
11. Bugajski A.J., Zurowski D., Thor P., Gadek-Michalska A. Effect of subdiaphragmatic vagotomy and cholinergic agents in the hypothalamic-pituitary-adrenal axis activity. J. Physiol. Pharmacol. 2007, 58:335-347.
12. Buttini M., Yu G.Q., Shockley K., Huang Y., Jones B., Masliah E., Mallory M., Yeo T., Longo F.M., Mucke L. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J. Neurosci. 2002, 22:10539-10548.
13. Chapman S., Michaelson D.M. Specific neurochemical derangements of brain projecting neurons in apolipoprotein E-deficient mice. J. Neurochem. 1998, 70:708-714.
14. Chapman S., Sabo T., Roses A.D., Michaelson D.M. Reversal of presynaptic deficits of apolipoprotein E-deficient mice in human apolipoprotein E transgenic mice. Neuroscience 2000, 97:419-424.
15. Christian K.M., Thompson R.F. Neural substrates of eyeblink conditioning: acquisition and retention. Learn. Mem. 2003, 10:427-455.
16. Claus J.J., Dubois E.A., Booij J., Habraken J., de Munck J.C., van Herk M., Verbeeten B., van Royen E.A. Demonstration of a reduction in muscarinic receptor binding in early Alzheimer's disease using iodine-123 dexetimide single-photon emission tomography. Eur. J. Nucl. Med. 1997, 24:602-608.
17. Cummings J.L. Cholinesterase inhibitors: a new class of psychotropic compounds. Am. J. Psychiatry 2000, 157:4-15.
18. de Bruin N.M., Fransen F., Duytschaever H., Grantham C., Megens A.A. Attentional performance of (C57BL/6Jx129Sv)F2 mice in the five-choice serial reaction time task. Physiol. Behav. 2006, 89:692-703.
19. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., van Duijn C.M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997, 278:1349-1356.
20. Fisher A., Brandeis R., Chapman S., Pittel Z., Michaelson D.M. M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice. J. Neurochem. 1998, 70:1991-1997.
21. Gaykema R.P., Gaal G., Traber J., Hersh L.B., Luiten P.G. The basal forebrain cholinergic system: efferent and afferent connectivity and long-term effects of lesions. Acta Psychiatr. Scand. Suppl. 1991, 366:14-26.
22. Gershon J. A meta-analytic review of gender differences in ADHD. J. Atten. Disord. 2002, 5:143-154.
23. Geula C., Mesulam M.M. Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease. Cereb. Cortex 1996, 6:165-177.
24. Gill T.M., Sarter M., Givens B. Sustained visual attention performance-associated prefrontal neuronal activity: evidence for cholinergic modulation. J. Neurosci. 2000, 20:4745-4757.
25. Gordon I., Grauer E., Genis I., Sehayek E., Michaelson D.M. Memory deficits and cholinergic impairments in apolipoprotein E-deficient mice. Neurosci. Lett. 1995, 199:1-4.
26. Humby T., Laird F.M., Davies W., Wilkinson L.S. Visuospatial attentional functioning in mice: interactions between cholinergic manipulations and genotype. Eur. J. Neurosci. 1999, 11:2813-2823.
27. Jaarsma D., Ruigrok T.J., Caffe R., Cozzari C., Levey A.I., Mugnaini E., Voogd J. Cholinergic innervation and receptors in the cerebellum. Prog. Brain Res. 1997, 114:67-96.
28. Jones C.K., Shannon H.E. Muscarinic cholinergic modulation of prepulse inhibition of the acoustic startle reflex. J. Pharmacol. Exp. Ther. 2000, 294:1017-1023.
29. Kleifeld O., Diebler M.F., Chapman S., Oron L., Michaelson D.M. The effects of apolipoprotein E deficiency on brain cholinergic neurons. Int. J. Dev. Neurosci. 1998, 16:755-762.
30. Koch H.J., Haas S., Jurgens T. On the physiological relevance of muscarinic acetylcholine receptors in Alzheimer's disease. Curr. Med. Chem. 2005, 12:2915-2921.
31. Krzywkowski P., Ghribi O., Gagne J., Chabot C., Kar S., Rochford J., Massicotte G., Poirier J. Cholinergic systems and long-term potentiation in memory-impaired apolipoprotein E-deficient mice. Neuroscience 1999, 92:1273-1286.
32. Lai M.K., Tsang S.W., Garcia-Alloza M., Minger S.L., Nicoll J.A., Esiri M.M., Wong P.T., Chen C.P., Ramirez M.J., Francis P.T. Selective effects of the APOE epsilon4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer's disease. Neurobiol. Dis. 2006, 22:555-561.
33. Lee T., Kim J.J. Differential effects of cerebellar, amygdalar, and hippocampal lesions on classical eyeblink conditioning in rats. J. Neurosci. 2004, 24:3242-3250.
34. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240:622-630.
35. Mahley R.W., Rall S.C. Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genom. Hum. Genet. 2000, 1:507-537.
36. Mirza N.R., Stolerman I.P. The role of nicotinic and muscarinic acetylcholine receptors in attention. Psychopharmacology (Berl.) 2000, 148:243-250.
37. Palacios J.M. Autoradiographic localization of muscarinic cholinergic receptors in the hippocampus of patients with senile dementia. Brain Res. 1982, 243:173-175.
38. Patel S., Stolerman I.P., Asherson P., Sluyter F. Attentional performance of C57BL/6 and DBA/2 mice in the 5-choice serial reaction time task. Behav. Brain Res. 2006, 170:197-203.
39. Paterson D., Nordberg A. Neuronal nicotinic receptors in the human brain. Prog. Neurobiol. 2000, 61:75-111.
40. Perry R.J., Hodges J.R. Attention and executive deficits in Alzheimer's disease, a critical review. Brain 1999, 122(Pt 3):383-404.
41. Plappert C.F., Pilz P.K., Schnitzler H.U. Factors governing prepulse inhibition and prepulse facilitation of the acoustic startle response in mice. Behav. Brain Res. 2004, 152:403-412.
42. Poirier J., Delisle M.C., Quirion R., Aubert I., Farlow M., Lahiri D., Hui S., Bertrand P., Nalbantoglu J., Gilfix B.M., Gauthier S. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:12260-12264.
43. Porter A.C., Bymaster F.P., DeLapp N.W., Yamada M., Wess J., Hamilton S.E., Nathanson N.M., Felder C.C. M1 muscarinic receptor signaling in mouse hippocampus and cortex. Brain Res. 2002, 944:82-89.
44. Probst A., Cortes R., Ulrich J., Palacios J.M. Differential modification of muscarinic cholinergic receptors in the hippocampus of patients with Alzheimer's disease: an autoradiographic study. Brain Res. 1988, 450:190-201.
45. Raber J. Androgens, apoE, and Alzheimer's disease. Sci. Aging Knowl. Environ. 2004, 2004:re2.
46. Raber J., Akana S.F., Bhatnagar S., Dallman M.F., Wong D., Mucke L. Hypothalamic-pituitary-adrenal dysfunction in Apoe(-/-) mice: possible role in behavioral and metabolic alterations. J. Neurosci. 2000, 20:2064-2071.
47. Raber J., Wong D., Buttini M., Orth M., Bellosta S., Pitas R.E., Mahley R.W., Mucke L. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:10914-10919.
48. Reid R.T., Sabbagh M.N., Thal L.J. Does apolipoprotein E (Apo-E) genotype influence nicotinic receptor binding in Alzheimer's disease. J. Neural Transm. 2001, 108:1043-1050.
49. Robbins T.W. The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl.) 2002, 163:362-380.
50. Salehi A., Dubelaar E.J., Mulder M., Swaab D.F. Aggravated decrease in the activity of nucleus basalis neurons in Alzheimer's disease is apolipoprotein E-type dependent. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:11445-11449.
51. Saunders A.M., Strittmatter W.J., Schmechel D., George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crapper-MacLachlan D.R., Alberts M.J., et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993, 43:1467-1472.
52. Schwab C., Bruckner G., Rothe T., Castellano C., Oliverio A. Autoradiography of muscarinic cholinergic receptors in cortical and subcortical brain regions of C57BL/6 and DBA/2 mice. Neurochem. Res. 1992, 17:1057-1062.
53. Shors T.J., Weiss C., Thompson R.F. Stress-induced facilitation of classical conditioning. Science 1992, 257:537-539.
54. Svensson A.L., Warpman U., Hellstrom-Lindahl E., Bogdanovic N., Lannfelt L., Nordberg A. Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotypes. Neurosci. Lett. 1997, 232:37-40.
55. Takatsuki K., Kawahara S., Mori H., Mishina M., Kirino Y. Scopolamine impairs eyeblink conditioning in cerebellar LTD-deficient mice. Neuroreport 2002, 13:159-162.
56. Ueki A., Goto K., Sato N., Iso H., Morita Y. Prepulse inhibition of acoustic startle response in mild cognitive impairment and mild dementia of Alzheimer type. Psychiatry Clin. Neurosci. 2006, 60:55-62.
57. Vaucher E., Reymond I., Najaffe R., Kar S., Quirion R., Miller M.M., Franklin K.B. Estrogen effects on object memory and cholinergic receptors in young and old female mice. Neurobiol. Aging 2002, 23:87-95.
58. von Bohlen O., Dermietzel H. Neurotransmitters and Neuromodulators: Handbook of Receptors and Biological Effects 2002, Wiley-VCH, Weinheim.
59. Watson M., Roeske W.R., Yamamura H.I. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes. J. Pharmacol. Exp. Ther. 1986, 237:419-427.
60. Whiteaker P., Jimenez M., McIntosh J.M., Collins A.C., Marks M.J. Identification of a novel nicotinic binding site in mouse brain using [(125)I]-epibatidine. Br. J. Pharmacol. 2000, 131:729-739.
61. Whitehouse P.J., Price D.L., Struble R.G., Clark A.W., Coyle J.T., Delon M.R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982, 215:1237-1239.
62. Woodruff-Pak D.S., Finkbiner R.G., Sasse D.K. Eyeblink conditioning discriminates Alzheimer's patients from non-demented aged. Neuroreport 1990, 1:45-48.
63. Woodruff-Pak D.S., Green J.T., Pak J.T., Heifets B., Pak M.H. The effect of scopolamine in older rabbits tested in the 750ms delay eyeblink classical conditioning procedure. Integr. Physiol. Behav. Sci. 2002, 37:103-113.
64. Woodruff-Pak D.S., Hinchliffe R.M. Mecamylamine- or scopolamine-induced learning impairment: ameliorated by nefiracetam. Psychopharmacology (Berl.) 1997, 131:130-139.
65. Young J.W., Crawford N., Kelly J.S., Kerr L.E., Marston H.M., Spratt C., Finlayson K., Sharkey J. Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur. Neuropsychopharmacol. 2007, 17:145-155.
66. Young J.W., Finlayson K., Spratt C., Marston H.M., Crawford N., Kelly J.S., Sharkey J. Nicotine improves sustained attention in mice: evidence for involvement of the alpha7 nicotinic acetylcholine receptor. Neuropsychopharmacology 2004, 29:891-900.